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Introduction: In 2019, Scotland reported the highest number of drug deaths amongst EU
countries. Of the 1,264 drug deaths reported in 2019, 94% were related to polysedative
use. Studies have proposed a relationship between opioid use and cardiovascular
disease. Furthermore, the concomitant use of sedatives and opioids has been
associated with lethal cardiopulmonary events. However, evidence is still limited for the
relationship between polysedative use and cardiovascular diseases. Thus, the present
study aimed to investigate the association between polysedative use and the underlying
cardiovascular pathologies in drug deaths.
Methods: This study consisted of a post-mortem investigation of 436 drug deaths. Data
extracted from post-mortem reports included socio-demographic characteristics (e.g.,
gender, age), cardiovascular pathologies (e.g., atherosclerosis, atheroma, and
inflammation), in addition to the presence of opioids (e.g. methadone, heroin) and
other substances (e.g., alcohol, benzodiazepine) in the blood of the deceased.
Stepwise multiple regression models were employed to identify which substances
predicted cardiovascular pathologies.
Results: The presence of opioids, benzodiazepines, and alcohol in the blood of the
deceased predicted overall cardiovascular disease (CVD) severity [R2  0.33, F (5, 430) 
39.64, p < 0.0001; adjusted R2  0.32, f2  0.49]. Positive Beta coefficients may indicate
an exacerbation of CVD (B  0.48 95% CI  0.25, 0.70) due to the presence of opioids in
the blood of the deceased. Negative associations may instead indicate a relative protective
effect of alcohol (B  −0.2, 95% CI  −0.41, −0.00) and benzodiazepines (B  −0.29, 95%
CI  −0.48, −0.09) on CVD.
Conclusion: These findings may inform national clinical guidelines on the need to monitor
individuals who abuse opioids for presence of cardiovascular disease risk factors
pathologies and provide timely interventions to reduce mortality in the population.
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INTRODUCTION
Substance use is associated with an alarmingly high morbidity
and mortality, creating challenges to health care systems around
the world (European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), 2021). Drug-related mortality accounts
for a substantial percentage of premature deaths in many
European countries among high-risk drug users (European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), 2021). In Europe, over 9,200 drug related deaths
(DDs) are reported yearly, of which opioid abuse contributes to
80–90% (European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA), 2021). In 2019, Scotland reported the
highest number of DDs amongst EU countries (National Records
of Scotland, 2019). According to The National Records of
Scotland (National Records of Scotland, 2019), 94% of DDs
consisted of polysedative users.
Specifically, of the 1,264 DDs reported in 2019, 1,205 were
related to opioid use (e.g., heroin, morphine, methadone), and
1,040 to additional street and/or prescribed benzodiazepine use
(e.g., diazepam, etizolam).
A retrospective cohort study concluded that the leading causes
of death related to opioid use are overdose, cardiovascular disease
(CVD), cancer, and infectious diseases (Hser et al., 2019). Other
studies have linked adverse cardiovascular effects such as
coronary heart disease (CHD) (Khodneva et al., 2016),
arrhythmia (Doshi et al., 2019a), cardiac arrest (Morrow et al.,
2019), and ischemic events (Doshi et al., 2019b) with prescribed
opioids and/or opioid overdose.
However, there are conflicting results regarding the
relationship between opioid use and CVD. Some studies failed
to find any association between chronic opioid use with the
increased risk of CVD (Chen and Ashburn, 2015; Chou et al.,
2015). A recent survey conducted in 2019, found no association
between the use of opioids and CHD (Ogungbe et al., 2019).
Interestingly, a review paper suggested a protective role of opioids
against myocardial ischemia and reperfusion injury (Tanaka
et al., 2014). Other studies investigating the risk of mortality
of long-acting opioids prescribed to patients suffering from
chronic noncancer pain (Ray et al., 2016) revealed a
1.64 times greater mortality risk compared to matched
patients who were prescribed other medication (anticonvulsant
or antidepressant) (Ray et al., 2016).
Evidence is also limited about the possible effects of
polysedative use on CVD. In fact, while the use of
benzodiazepines alone has been associated to reduced risk of
CVD (Balon et al., 2018), the concomitant use of benzodiazepines
and opioids has been associated with an increased risk of adverse
cardiopulmonary events (e.g., respiratory depression) (Yang
et al., 2020; Jones et al., 2012). Furthermore, a recent
epidemiological study conducted by Tori et al., 2020, in the
US revealed a 10.3-fold increase in the mortality rates for
opioid overdose deaths involving benzodiazepines, and a
5.5-fold increase in opioid overdose deaths involving alcohol
from 1999 to 2017. Indeed, chronic consumption of alcohol has
been also associated with a higher risk of CHD (Jalali et al., 2021).
Therefore, there is an urgent need for better understanding the
role of opioids and other sedatives in CVD mortality given that
opioids, benzodiazepines and alcohol are consumed by
individuals with substance use disorder and also by patients
admitted with acute myocardial infarction. Additionally, recent
studies have suggested that SARS-CoV-2, which causes COVID-
19, affects the endothelial system (Sardu et al., 2020), which is a
major regulator of cardiovascular health. Specifically, these
studies showed that the virus gains entry to host cells via
angiotensin-converting enzyme 2 (ACE2), which could cause
myocardial dysfunction, plaque instability, microvascular
dysfunction, myocardial infraction (MI), and endothelial
dysfunction (Guzik et al., 2020). Given the effect of COVID-
19 on the endothelium, and the possible increase in long-term
CVDmorbidity and mortality related to chronic opioid and other
sedative use, it is important that this association is studied further
to protect patients against the adverse effects of COVID-19 and
several other groups of patients who have compromised
cardiovascular health. Given the previously quoted studies
showing an increase in long-term CVD morbidity related to
opioid use, and a synergic effect of opioids and other sedative use
on adverse cardiopulmonary events, it is important to better
understand this in patients who have CVD. Thus, the present
study examines post-mortem data and aims to investigate the
association between opioid and other sedative use and the




Post-mortem reports (PMRs) of individuals deceased between
2013–2019 within the Fife administrative region (Scotland,
United Kingdom) with inclusion criteria of DD were
anonymized by AB and FD and made available for the study
(n  436).
Details of CVD pathologies identified by post-mortem
histological examinations were also extracted from each PMR.
A total of twelve CVD pathologies were identified by screening all
436 PMRs. These included atherosclerosis (left, right, aorta),
atheroma (left, right, aorta), fibrosis, hypertrophy,
inflammation, and stenosis (proximal, middle, distal).
Pathologies were defined by a Consultant Pathologist based on
the histological examination of tissues gained from deceased
subjects. A numerical score ranging from 0 to 3 was attributed
to each pathology according to its reported severity (0 No CVD,
1  Mild, 2  Moderate, and 3  Severe). CVD severity was
described in each PMR by the Consultant Pathologist who
performed the histological examination. To facilitate statistical
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analyses, severity sub-scores for atherosclerosis (left, right, aorta),
atheroma (left, right, aorta), and stenosis (proximal, middle,
distal) were combined into a cumulative score for each
pathology. Specifically, cumulative severity scores were
provided for atheroma, atherosclerosis, and stenosis. These
scores ranged from 0 (no CVD) to 9 (severe CVD).
Additionally, a “total” CVD severity score was calculated for
each PMR by combining the scores of all pathologies
(atherosclerosis, atheroma, stenosis, fibrosis, inflammation,
hypertrophy). This score ranged from 0 (no CVD) to 36
(severe CVD).
Research, Ethical and Information
Governance Approvals
A request for research access to clinical data relating to the
deceased must be treated in the same way as one for data
relating to the living. The proposal was considered by NHS
Fife Research and Development (R and D) Department,
South-East Scotland Regional Ethics Department and NHS
Fife Caldicott Guardian on its own merits as per any other
project. As our study did not involve NHS clinical time, and
the post-mortem data were obtained through a multiagency
information sharing memorandum of understanding (2010) to
share and disseminate findings of the DDs in Fife in aggregate
forms, it was not deemed as research by NHS Fife R and D
Department. The secondary analysis of post-mortem results did
not need ethical approval. Handling of health-related data of a
deceased individual does not need consent, as one relies on other
legal bases than consent for processing these data. Whilst the
deceased did not have the protection of the Data Protection Act,
the advice was that the process of this information should still
enshrine a duty of confidentiality, so all the normal data security
safeguards were put in place. The study was therefore approved
by NHS Fife Caldicott Guardian in 2012.
Drug Deaths
The definition of a drug death (DD) is complex, with individual
studies adopting specific definitions, which vary depending upon
the focus of the study. The Scottish Criminal Drugs Enforcement
Agency (SCDEA) defines a DD as: ‘‘Where there is prima facie
evidence of a fatal overdose of controlled drugs. Such evidence
may be recent drug misuse, for example, controlled drugs and/or
a hypodermic syringe found in close proximity to the body and/or
the person is known to the police as a drug misuser although not
necessarily a notified addict.”
The complexity of providing a suitable DD definition is
demonstrated by the differences in definitions incorporated by
different organisations. For example, the World Health
Organisation.
(WHO) defines it as “fatal consequences of the abuse of
internationally controlled substances and/or of non-medical
use of other substances for psychic effects,” (World Health
Organization, 1993). This definition allows the incorporation
of deaths indirectly associated with drug abuse, which would
be excluded by the SCDEA, such as chronic intoxication, suicide,
drug abuse-related accidents, and drug-abuse related diseases.
This definition is similar, but not identical, to the definition
employed by the General Register Office for Scotland (GROS).
The GROS definition includes instances in which toxicological
findings indicate the presence of a controlled substance, but
where this substance may not necessarily have been a factor
contributing to the individual’s death.
Inclusion and Exclusion Criteria
The inclusion/exclusion criteria presented below incorporates the
International Classification of Diseases ICD-10 (F, X, Y) codes
used to identify relevant reports for analysis:
Inclusion criteria included:
1) DD, where the underlying cause of death has been coded to
the following sub-categories of “mental and behavioural
disorders due to psychoactive substance use”: opioids
(F11), cannabinoids (F12), sedatives or hypnotics (F13),
cocaine (F14), other stimulants, including caffeine (F15),
hallucinogens (F16), and multiple drug use and use of
other psychoactive substances (F19).
2) deaths coded to the following categories and where a drug
listed under the Misuse of Drugs Act (1971) was known to be
present in the body at the time of death: accidental poisoning
(X40-X44), intentional self-poisoning by drugs, medicaments,
and biological substances (X60—X64), assault by drugs,
medicaments, and biological substances (X85) and event of
undetermined intent, poisoning (Y10-Y14).
Exclusion criteria included:
1) deaths coded to mental and behavioural disorders due to the
use of alcohol (F10), tobacco (F17), and volatile
substances (F18).
2) deaths coded to drug abuse which were caused by secondary
infections and related complications (e.g., septicaemia).
3) deaths from AIDS where the risk factor was believed to be the
sharing of needles.
4) deaths where a drug listed under the Misuse of Drugs Act was
present because it was part of a compound analgesic or cold
remedy, e.g., co-proxamol: paracetamol, dextropropoxyphene
or co-dydramol: paracetamol, dihydrocodeine or co-codamol:
paracetamol, codeine sulphate as all three of these compound
analgesics have, particularly co-proxamol, been used in
suicidal overdoses.
Data Extraction
Data pertaining to relevant socio-demographic characteristics were
extracted from each PMR. These included age at the time of death,
biological sex, and body mass index (BMI). The presence (or not)
of psychoactive substances and/or medicinal drugs, as described in
each PMR, was determined by inspecting results of abdominal
blood, femoral blood, or ilio-femoral analyses detailed in the
toxicology report of each PMR. Substances were grouped into
drug classes (opioids, stimulants, anticonvulsants, Tricyclic
Antidepressants (TCA), and Selective Serotonin Reuptake
Inhibitors (SSRI), benzodiazepines, anticonvulsants, alcohol, and
cannabinoids) according to their chemical compounds.
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Statistical Analysis
Frequencies procedures were conducted to determine the
percentages (%) of males, females, and of drug classes
identified in the sample comprising of 436 deceased
individuals. Descriptive statistics were computed to determine
the mean and standard deviation (SD) for continuous
demographic variables such as age and BMI, and for severity
scores of each CVD pathology.
Categorical variables were utilized to determine the
presence (or not) of each drug class in post-mortem cases.
Specifically, a numerical value of 0 was attributed if
concentrations of a particular drug class were not detected
by post-mortem blood analyses (e.g., no substances
containing opioid compounds such as morphine, codeine,
norbuprenorphine, methadone were identified by blood
analyses). A numerical value of 1 was instead attributed if
concentrations of a particular drug class were detected by
post-mortem blood analyses. Drug classifications and
categorical values were employed to minimize issues of
heterogeneity related to different units of measurements
(e.g., mg/dl, g/l), types of substances, and respective
metabolites listed in each PMR. A stepwise multiple
regression model with a “backward” procedure (Field,
2009) was computed for each CVD pathology and for the
total CVD severity score. Thus, seven regression models were
computed. This identified which drug classes and
demographic variables best predicted CVD severity.
Specifically, all drug classes (opioids, stimulants, alcohol,
anticonvulsants, cannabis, TCAs, SSRIs, benzodiazepines)
and all demographic characteristics (age at the time of
death, BMI, biological sex) were included simultaneously
in the first step of each regression model as independent
variables (IVs).
Females were coded as 0 andmales coded as 1. The presence of
a drug class was coded as 1 while the absence was coded as 0.
Continuous dependent variables (DVs) consisted in the severity
scores computed for each pathology (stenosis, atherosclerosis,
atheroma, inflammation, hypertrophy, fibrosis) and in the total
CVD severity score. The IVs that contributed less to the
regression equation (p > 0.1) were removed from each model
sequentially (Székely et al., 2006; Okamoto et al., 2016). The last
step of each regression model included the drug classes and/or the
demographic variables that best predicted CVD severity.
Statistical significance was set as p < 0.05 (Cohen, 1970).
Effect sizes (f2)for multiple regression models were computed




1 − R2 (1)
Where R2  coefficient of multiple determination.
An effect size (f2) of 0.02 implies a small effect size, an effect
size (f2) of 0.15 implies a medium effect size, and an effect size (f2)
of 0.35 implies a large effect size according to Cohen’s benchmark
criteria (Cohen, 1988). Assumptions for stepwise multiple
regression models included 1) normally distributed residuals,
2) no multicollinearity, and 3) no highly influential points.
The assumption of no highly influential points was assessed by
inspecting Cook’s values computed by each regression model
(Cook and Weisberg, 1982). A Cook’s value > 1.00 implies a
highly influential point. Variance Inflation Factor (VIF) values >
10.00 indicate multicollinearity (Hair et al., 2014). The
assumption of normally distributed residuals was assessed by
conducting Kolmogorov Smirnoff tests on studentized residuals.
A Kolmogorov Smirnoff test result of p < 0.05 indicates non-
normally distributed residuals. If the assumption of normality
was violated, a SQRT transformation was attempted. If the
assumption of normality was violated after SQRT
transformation, the regression models were still computed. In
fact, multiple regression is considered robust against violations of
normality when dealing with large sample sizes (>10 observations
per variable) (Schmidt and Finan, 2018). As stated by Ernst and
Alberts (2017) “the central limit theorem implies that for large
samples the sampling distribution of the parameters will be at
least approximately normal, even if the distribution of the errors
is not. Hence, the regression model is robust with respect to
violations of the normality assumption” (Ernst and Albers, 2017).





Sociodemographic characteristics at the time of death and drug
classes identified in the 436 PMRs are depicted in Tables 1, 2.
TABLE 1 | Demographic characteristics at the time of death and drug classes
identified in 436 PMRs.
Variable N (%) M SD Observed range
Demographics
Age at the time of death (years) — 40.0 10.3 18.0–73.0
































Note. SSRI, Serotonin Reuptake Inhibitor; TCA, Tricyclic Antidepressants; N, number of
cases; %, percentage; M, Mean; SD, Standard Deviation.
Frontiers in Pharmacology | www.frontiersin.org November 2021 | Volume 12 | Article 7250344
Arab et al. Polysedative and CVD in DD
CVD pathologies and their respective severity scores are listed in
Table 3.
Tables 1, 2 show that most post-mortem cases comprised of
middle aged male polysubstance users. BMI data revealed that
cases were of normal weight at the time of death according to the
Centre for Disease and Control prevention (Centre for Disease
Control and Prevention, 2019) cut-off score of <25 kg/m2. Mild
CVD was identified in most cases (n  345). The most common
observed CVD pathologies were atheroma (n  243) and fibrosis
(n  226) and the least common were stenosis (n  54) and
inflammation (n  50).
Multiple Regression
Results of the regression model predicting total CVD severity
score are depicted in Table 4. Results of regression models
predicting the severity of atheroma, fibrosis, atherosclerosis,
inflammation, stenosis, and hypertrophy are depicted in
Supplementary Tables 1–6.
The model including age, biological sex, opioids, alcohol, and
benzodiazepines (Step 7) represented the best fit for the regression
equation predicting total CVD severity [R2  0.33, F (5, 430) 
39.64, p < 0.0001; adjusted R2  0.32, f2  0.49]. Atheroma severity
was best predicted by a model including age, opioids, alcohol, and
benzodiazepines [R2  0.22, F (6, 429)  20.13, p < 0.0001; adjusted
R2  0.20, f2  0.28] (Step 6 in Supplementary Table 1). Similarly,
the best regression model predicting fibrosis severity included age,
alcohol, and benzodiazepines (Step 9 in Supplementary Figure 2)
[R2  0.14, F (3, 432)  24.76, p < 0.0001; adjusted R2  0.14, f2 
0.16]. Inflammation was best predicted by a model including age
and opioids [R2  0.02, F (2, 433)  4.96, p < 0.01; adjusted R2 
0.02, f2  0.02]. However, only opioids predicted inflammation
significantly (p < 0.05) at the last stage of the backward procedure
(Step 10 in Supplementary Table 3).
Hypertrophy severity was predicted significantly by BMI and
alcohol (p < 0.05) at the last step of the regression model [R2 
0.02, F (3, 432)  4.13, p < 0.01; adjusted R2  0.02, f2  0.02] (Step
9 in Supplementary Table 4). Severity of atherosclerosis was best
predicted by age and biological sex [R2  0.07, F (2, 433)  16.61,
p < 0.0001; adjusted R2  0.06, f2  0.07] (Step 10 in
Supplementary Table 5). Age was instead the only variable to
predict significantly (p < 0.05) stenosis’ severity [R2  0.01, F (1,
434)  6.72, p < 0.05; adjusted R2  0.01, f2  0.01] (Step 11 in
Supplementary Table 6).
By looking at R2 statistics and effect sizes described above, it
can be noted that total CVD severity score, atheroma, and fibrosis
pathologies were strongly influenced by opioids, alcohol, and
benzodiazepines. Negative unstandardized Beta coefficients may
suggest a relative protective effect of benzodiazepines (B  −0.29,
95% CI  −0.48, −0.09) and alcohol (B  −0.2, 95% CI  −0.41,
−0.00) on CVD. On the other hand, positive Beta coefficients may
indicate a worsening of CVD due to a higher presence of opioids
in the blood of the deceased (B  0.48, 95% CI  0.25, 0.70).
Opioids were particularly relevant in predicting total CVD score
and atheroma severity.
TABLE 2 | Drug classification based on chemical compounds of substances identified in the 436 PMRs.
Opioids Stimulants TCAs SSRIs Benzodiazepines Anticonvulsants
Methadone Amphetamine Amitriptyline Sertraline Alprazolam Gabapentin
Buprenorphine Cocaine Mirtazapine Fluoxetine Diazepam Pregabalin
Norbuprenorphine MDMA — Citalopram Etizolam —
Codeine — — — — —
Dihydrocodeine — — — — —
Morphine, 6- — — — — —
Monoacetylmorphine — — — — —
Tramadol, Oxycodone — — — — —
Note. TCA, Tricyclic Antidepressants; SSRI, Serotonin Reuptake Inhibitor; MDMA, methylenedioxy-methamphetamine.
TABLE 3 | Severity scores for cardiovascular pathologies identified in 436 Post-mortem Reports (PMRs).





Atherosclerosis 0.7 1.5 0–9 110 (25.2)
Stenosis 1.5 1.9 0–9 54 (12.3)
Atheroma 0.3 1.1 0–9 243 (55.7)
Inflammation 0.1 0.5 0–3 50 (11.4)
Hypertrophy 0.2 0.6 0–3 69 (15.8)
Fibrosis 0.8 0.9 0–3 226 (51.8)
Total CVD 3.9 3.8 0–22 345 (79.1)
Note. The severity score for atherosclerosis (0  no CVD to 9  severe CVD) was obtained by combining scores for left, right, and aorta atherosclerosis. The severity score for atheroma (0 
no CVD to 9  severe CVD)was obtained by combining scores for left, right, and aorta atheroma. The severity score for stenosis (0 noCVD to 9  severe CVD) was obtained by combining
scores for proximal, middle, and distal stenosis. The total CVD severity score (0  no CVD to 36  severe CVD) was obtained by combining scores for atherosclerosis, stenosis, atheroma,
inflammation, hypertrophy, and fibrosis.
M, Mean; SD, Standard deviation; N, number of cases; %, Percentage. PMRs, Post-mortem reports; CVD, cardiovascular disease.
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TABLE 4 | Stepwise multiple regression model with backward procedure predicting total cardiovascular disease (CVD) severity from age, BMI, sex, opioids, alcohol,
cannabis, stimulants, benzodiazepines, TCAs, anticonvulsants, and SSRIs in 436 post-mortem cases.
B SE 95% CI p R R2 Adjusted R2
Step 1 — — — — 0.58 0.34 0.32
Constant −0.72 0.30 −1.31, −0.13 0.017 — — —
BMI 0.00 0.00 −0.00, −02 0.35 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.27 0.11 0.05, 0.49 0.013 — — —
Opioids 0.45 0.11 0.21,0.68 0.00a — — —
Alcohol −0.22 0.10 −0.42, −0.01 0.039 — — —
Cannabis −0.07 0.11 −0.30, 0.15 0.52 — — —
Stimulants −0.10 0.13 −0.38, 0.16 0.43 — — —
Benzodiazepines −0.25 0.11 −0.48, 0.02 0.03 — — —
TCAs 0.07 0.13 −0.18, 0.32 0.57 — — —
Anticonvulsants −0.10 0.12 −0.35, 0.14 0.40 — — —
SSRIs −0.11 0.14 −0.40, 0.18 0.45 — — —
Step 2 — — — — 0.58 0.34 0.32
Constant −0.72 0.30 −1.31, 0.13 0.017 — — —
BMI 0.00 0.00 −0.00, 0.02 0.36 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.27 0.11 0.05, 0.49 0.014 — — —
Opioids 0.45 0.11 0.21, 0.68 0.00a — — —
Alcohol −0.22 0.10 −0.43, 0.01 0.038 — — —
Cannabis −0.06 0.11 −0.28, 0.16 0.58 — — —
Stimulants −0.11 0.13 −0.38, 0.15 0.39 — — —
Benzodiazepines −0.24 0.11 −0.46, −0.01 0.035 — — —
Anticonvulsants −0.09 0.12 −0.34, 0.15 0.44 — — —
SSRIs −0.10 0.14 −0.38, 0.18 0.48 — — —
Step 3 — — — — 0.58 0.34 0.32
Constant −0.76 0.29 −1.33, −0.18 0.01 — — —
BMI 0.00 0.00 −0.00, 0.02 0.33 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.27 0.11 0.05, 0.49 0.014 — — —
Opioids 0.45 0.11 0.22, 0.68 0.00a — — —
Alcohol −0.21 0.10 −0.42, −0.00 0.041 — — —
Stimulants −0.11 0.13 −0.38, 0.15 0.39 — — —
Benzodiazepines −0.25 0.11 −0.47, 0.03 0.025 — — —
Anticonvulsants −0.09 0.12 −0.34, 0.15 0.43 — — —
SSRIs −0.09 0.14 −0.38, 0.18 0.49 — — —
Step 4 — — — — 0.58 0.34 0.32
Constant −0.78 0.29 −1.35, −0.20 0.008 — — —
BMI 0.00 0.00 −0.00, 0.02 0.32 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.27 0.11 0.06, 0.49 0.013 — — —
Opioids 0.46 0.11 0.23, 0.68 0.00a — — —
Alcohol −0.21 0.10 −0.42, −0.00 0.041 — — —
Stimulants −0.11 0.13 −0.38, 0.15 0.41 — — —
Benzodiazepines −0.25 0.11 −0.47, −0.03 0.022 — — —
Anticonvulsants −0.09 0.12 −0.34, 0.15 0.45 — — —
Step 5 — — — — 0.58 0.34 0.32
Constant −0.77 0.29 −1.35, −0.20 0.008 — — —
BMI 0.00 0.00 −0.00, 0.02 0.38 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.28 0.11 0.06, 0.50 0.010 — — —
Opioids 0.46 0.11 0.23, 0.69 0.00a — — —
Alcohol −0.21 0.10 −0.42, −0.00 0.040 — — —
Stimulants −0.11 0.13 −0.38, 0.15 0.39 — — —
Benzodiazepines −0.29 0.09 −0.49, −0.10 0.003 — — —
Step 6 — — — — 0.58 0.33 0.32
Constant −0.82 0.28 −1.39, −0.26 0.004 — — —
BMI 0.00 0.00 −0.00, 0.02 0.35 — — —
Age 0.04 0.00 0.03, 0.05 0.00a — — —
Biological sex (Male) 0.27 0.11 0.06, 0.49 0.012 — — —
Opioids 0.47 0.11 0.25, 0.70 0.00a — — —
Alcohol −0.22 0.10 −0.42, −0.01 0.036 — — —
Benzodiazepines −0.29 0.09 −0.49, −0.10 0.003 — — —
(Continued on following page)
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Furthermore, the presence of opioids in post-mortem cases
was correlated to cardiovascular inflammation, albeit with a very
small effect size (f2  0.02). Severity of hypertrophy,
atherosclerosis, and stenosis were not predicted by any drugs.
These pathologies were best predicted by demographic
characteristics (e.g., BMI, age, biological sex). However, low R2
values and small effect sizes may indicate that other variables not
included in the regression models (e.g., diet, genetic
susceptibility) may have constituted better predictors.
DISCUSSION
Summary of Results
This is the first post-mortem study in the literature, to the best of
our knowledge, that investigated the relationship between
substance use and CVD pathology in DDs. Our study showed
similar descriptive statistics to the 2021 EMCDDA report
(European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), 2021) by revealing the presence of opioids in 77% of
DDs and therefore, confirming opioid abuse as the fulcrum of
Scotland’s drug crisis. Notably, our study revealed an association
between the presence of opioids in the system of post-mortem
cases and total CVD severity. A relationship was also identified
between the presence of opioids and CVD pathologies such as
inflammation and atheroma, which are known to lead to
atherosclerosis (Hansson, 2009). These findings are consistent
with the current literature showing an association between opioid
use and poor CVD outcomes (Ziaee et al., 2019). Specifically, a
recent literature review conducted by Ziaee et al. (2019) proposed
a correlation between chronic opioid use and ischemic stroke.
Furthermore, longer duration and higher dosage of opioids were
associated with hypertension and with an elevated susceptibility
to CHD (Ziaee et al., 2019).
Opioids may have reversed a seemingly cardiovascular
protective effect associated to alcohol and benzodiazepines
use. Notably, a recent meta-analysis conducted by Yoon et al.
(2020) revealed a protective effect of moderate and light
alcohol consumption on CVD incidence for individuals
aged over 40 years not presenting comorbid conditions.
Regarding benzodiazepines, Colussi et al. (2011) revealed
low doses of Midazolam to produce a vasodilatation of
aortic rings in mice. A retrospective study conducted by
Mendelson et al. (2018) revealed chronic benzodiazepines
users to present lower blood pressure in comparison to
non-benzodiazepines users.
Findings from the current study do not exclude a possible
synergic effect of opioids, alcohol, and benzodiazepines on lethal
cardiopulmonary events for individuals suffering from CVDs.
Indeed, while there is limited and contrasting evidence for the
effect of alcohol and benzodiazepines alone on CVD (Balon et al.,
2018; Theofilis et al., 2020), the concomitant abuse of alcohol and
benzodiazepinesmay cause cardiovascular and pulmonary toxicity,
ultimately leading to cardio-respiratory arrest (Mari et al., 2013).
The proposed synergic effect of opioids and other sedatives on
adverse cardiopulmonary events may be in line with a study
conducted by Izrailtyan et al. (2018), which showed prescribed
opioids and sedatives to be independently associated with the risk
of cardiopulmonary arrest in 14,504,809 medical in-patients and
6,771,882 surgical in-patients. The authors also stated that “as
compared to patients who received treatment with opioids only,
those who received additional sedative medications had a twofold
increase in the risk of developing cardiopulmonary arrest”
(Izrayltian et al., 2018). Additionally, a recent literature review
conducted by Boon et al. (2020) revealed the concomitant use of
opioids and benzodiazepines to be associated with an increased
risk of suffering lethal respiratory depression in both clinical and
non-clinical settings. The above inferences, however, remain
highly speculative due to the cross-sectional nature of the
current post-mortem study.
The effect of opioids on CVD may have also been influenced
by demographic characteristics such as gender and age. In fact,
consistently with the literature (North and Sinclair, 2012), older
age was predictive of most CVD pathologies (atheroma, fibrosis,
atherosclerosis, stenosis).
Notably, an observational cohort study conducted by Gao et al.
(2019) revealed that circulatory disease was featured in 11% of all
methadone specific DDs occurred in Scotland from 2009 to 2015.
Furthermore, circulatory disease was mentioned in 18% of
methadone specific DDs occurred at 45 years of age or later.
Thus, suggesting a unique adverse effect of methadone on older
individuals with underlying CVD pathologies.
The current study did also reveal a significant, albeit small,
association between the presence of opioids in post-mortem cases
TABLE 4 | (Continued) Stepwise multiple regression model with backward procedure predicting total cardiovascular disease (CVD) severity from age, BMI, sex, opioids,
alcohol, cannabis, stimulants, benzodiazepines, TCAs, anticonvulsants, and SSRIs in 436 post-mortem cases.
B SE 95% CI p R R2 Adjusted R2
Step 7 — — — — 0.58 0.33 0.32
Constant −0.66 0.22 −1.10, −.21 0.004 — — —
Age 0.04 0.00 0.04, 0.05 0.00a — — —
Biological sex (Male) 0.26 0.10 0.05, 0.48 0.014 — — —
Opioids 0.48 0.11 0.25, 0.70 0.00a — — —
Alcohol −0.21 0.10 −0.41, −0.00 0.043 — — —
Benzodiazepines −0.29 0.09 −0.48, −0.09 0.003 — — —
Note.
ap < 0.0001 level; B, unstandardised beta coefficient; SE, Standard Error; CI, Confidence Interval; R, correlation coefficient; R2, coefficient of multiple determination.
SSRI, serotonin selective reuptake inhibitors; BMI, body mass index; TCA, tricyclic antidepressants.
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and inflammation severity. Recently, research suggested that
chronic inflammation is one the leading causes of cardiac
diseases (Fioranelli et al., 2018).
Chronic opioid use has been shown to induce systemic
inflammation by exacerbating the up-regulation of pro-
inflammatory cytokines such as interleukin 6 (IL-6), C-reactive
protein (CRP), and tumour necrosis factor-α (TNF-α) (Lu et al.,
2019). Furthermore, the impact of opium addiction on high-
sensitivity CRP suggests that opium might cause accelerated
multi-system chronic inflammation and coronary
atherosclerosis (Reece, 2012). hs-CRP is known to be an
important molecular biomarker in activating innate and
adaptive immune response to inflammation (Reece, 2012). hs-
CRP is mainly produced under the influence of IL-6, and the
literature evidence suggests that hs-CRP is correlated with the
pathophysiology of atherosclerosis and coronary artery disease
(CAD) (Reece, 2012).
Further evidence suggests that opioids can elevate the level and
accelerate the formation of reactive oxygen species (ROS) which
results in vascular cell damage and endothelial dysfunction
(Zahmatkesh et al., 2017).
With the current pandemic of COVID-19, opioids use has also
contributed to increasing the risk of COVID-19 infection and the
risk of its adverse effects (Wang et al., 2021). Specifically, patients
diagnosed with substance use disorders were at about 8 times
higher risk of contracting and perishing from COVID-19
compared non-users. This risk was even greater for patients
affected by opioid use disorder (Wang et al., 2021). This could
be explained by the impact of opioids use on various mechanistic
pathways. For instance, considering that opioid use exacerbates the
up regulation of IL-6 (Lu et al., 2019), it may worsen the
inflammation and consequent cardiovascular outcomes (e.g.,
myocarditis, plaque rupture) related to the cytokine storm of L-
6, IL-7, and IL-22 induced by the viral invasion of SARS-CoV-2.
Limitations and Strengths
Strengths of the current study include its novelty and its relevance
for clinical and public health implications as will be elucidated in
the following section. Results from the current study should also
be considered in light of several limitations. The first being the
lack of a comparable healthy control group comprising of
deceased individuals who were not polysedative users. The
lack of a comparable group of living polysedative users may
also be considered a limitation as such group would have
provided context to the limited and opportunistic sample
comprising DDs. Methodological limitations include the
inability to extract dosage and duration of substance use due
to the nature of the information being obtained from
routine PMRs.
Furthermore, it was not possible to extract and to statistically
control for confounding factors (e.g., diet, physical exercise)
which are known to influence cardiovascular health. In fact,
by looking at regression models predicting inflammation,
hypertrophy, atherosclerosis, and stenosis it could be noted
that a high percentage of variance predicting such pathologies
remains unexplained (R2 values). For example, inflammationmay
have been also explained by chronic tobacco smoking. In fact,
according to a recent meta-analysis conducted by Doggui et al.
(2021) there is a robust correlation between chronic tobacco
smoking and systemic inflammation (high CRP levels). However,
data pertaining to chronic tobacco smoking were not available in
post-mortem reports. Additionally, due to the heterogeneity of
substances identified in post-mortem cases, it was not possible to
investigate the effect of specific substances (e.g., methadone VS
buprenorphine) on CVD. Therefore, there is a need for
conducting further empirical research investigating the impact
of opioids and other sedatives use on CVD in living individuals by
taking into-account the above-mentioned limitations.
Clinical and Public Health Relevance
This post-mortem study revealed a significant positive
association between opioids identified in the blood of post-
mortem cases and severity of CVD pathologies. Findings
from the current study have thepotential to inform
national clinical guidelines on the need to monitor
individuals who abuse opioids for signs of CVD and
provide timely interventions. In fact, the early
identification of high risk/at-risk opioid users would
contribute to the reduction of early morbidity/mortality in
this population. The cardiovascular health of individuals who
are prescribed opioids for long term pain relief should also be
monitored constantly. Furthermore, considering a possible
synergic effect of alcohol, benzodiazepines, andopioids on
lethal cardio-pulmonary events, caution should be exercised
in prescribing opioids to patients who are heavy alcohol
drinkers and/or currently using benzodiazepines.
The burden of worsening CVD outcomes that could be due to
chronic opioid use might also have public health consequences for
quality of life. One prominent example is the strong association
between CVD and depression (Hare et al., 2014). Therefore,
healthcare providers should also apply screening tools to assess
the psychological burden associated to the development of CVD in
high-risk populations such as opioids users. These populations
may be also affected by comorbid psychiatric conditions as
individuals may utilise substances such as benzodiazepines and
opioids concomitantly to self-medicate symptoms of anxiety or
mania (Jones et al., 2012; Vogel et al., 2013).
Moreover, given the effect of COVID-19 on the cardiovascular
system, and the possible increase in long-term CVD morbidity
related to opioids use, it is important that this association is
studied further to protect patients affected by COVID-19 and
several other groups of patients who have compromised
cardiovascular health.
CONCLUSION
A significant positive association was identified between opioids
use and CVD severity in DDs. These finding could contribute to
future evidence-based guidelines indicating more extensive CVD
monitoring in those clinical areas working with licit and illicit
opioids users. However, additional research into how/why/who/
when is affected would improve our understanding of this
mechanistic link.
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